Friday, October 11, 2024
HomeLatest Pharma-NewsJohnson & Johnson to Provide Webcast Fireside Chat on Clinical Data

Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data

May 18, 2020: “The Janssen Pharmaceutical Companies of Johnson & Johnson will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

The webcast is intended for investors and other interested parties and will be available beginning at 8:00 a.m ET on Tuesday, May 19, 2020.

The webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC, who will highlight key clinical data including updated results from the Phase 1b/2 CARTITUDE-1 study of the BCMA CAR-T (JNJ-68284528) in relapsed/refractory multiple myeloma, final overall survival results from the ERLEADA® (apalutamide) Phase 3 SPARTAN study in nonmetastatic castration-resistant prostate cancer, an update on Amivantamab (JNJ-61186372, EGFRxcMET bispecific antibody) in patients with exon20ins-mutated non-small cell lung cancer, and initial Phase 1 study results of Teclistamab (JNJ-64007957, BCMAxCD3 bispecific antibody) in relapsed/refractory multiple myeloma. Dr Lebowitz will also discuss the company’s oncology strategy and portfolio.

- Advertisement -

The webcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.” The webcast duration is approximately 30 minutes and will be available through the end of July.”
https://www.jnj.com/johnson-johnson-to-provide-webcast-fireside-chat-on-clinical-data-to-be-presented-at-the-american-society-of-clinical-oncology-and-the-janssen-oncology-strategy-and-portfolio

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular